Physician profile
Peter K Dunn
NPI 1619925799
$2,696.17
in general payments reported to CMS, 2019-2025
17 companies · $634 in 2025
The $634 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $125 · 2021: $116 · 2022: $516 · 2023: $244 · 2024: $231 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $521.06 | 2019-2025 | Precision7, Acrysof Iq Panoptix Uv Iol, Total30 |
| Johnson & Johnson Vision Care, INC. | $365.48 | 2022-2024 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $358.55 | 2019-2021 | |
| Allergan, INC. | $279.54 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $194.13 | 2024-2025 | Xdemvy |
| Coopervision INC. | $150.45 | 2021-2025 | Misight Contact Lens |
| Biotissue Holdings INC. | $146.12 | 2025 | |
| Sun Pharmaceutical Industries INC. | $138.17 | 2019 | |
| Optos, INC. | $133.24 | 2019 | |
| Bausch & Lomb Americas INC. | $88.34 | 2022-2025 | Vyzulta |
| Oyster Point Pharma, INC. | $79.43 | 2022-2023 | Tyrvaya |
| Apellis Pharmaceuticals, INC. | $66.04 | 2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $64.00 | 2019 | |
| Shire North American Group INC | $36.95 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.63 | 2019-2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.94 | 2025 | Izervay |
| Thea Pharma INC. | $19.10 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.